Efficacy and Safety of Bolus Injection of a Novel Thrombolytic Agent (SMRX-11) in Patients with Acute ST-segment Elevation Myocardial Infarction (STEMI): A Phase II Open-Label, Dose-Escalation, Multicentre, Angiographic Trial - SMRX-11

Start Date10 Mar 2014

Sponsor / Collaborator-

100 Clinical Results associated with SMRX-11

100 Translational Medicine associated with SMRX-11

100 Patents (Medical) associated with SMRX-11

Literatures (Medical) associated with SMRX-11

01 Aug 2022·Molecular Phylogenetics and EvolutionQ1 · BIOLOGY

Horizontal transfer of Buster transposons across multiple phyla and classes of animals

Q1 · BIOLOGY

Article

Author: Gao, Bo ; Song, Chengyi ; Shi, Shasha ; Diaby, Mohamed ; Danley, Patrick ; Guan, Zhongxia ; Puzakov, Mikhail ; Ullah, Numan

Transposable elements (TEs) are mobile genetic elements in the genome and broadly distributed across both prokaryotes and eukaryotes, and play an important role in shaping the genome evolution of their hosts. hAT elements are thought to be the most widespread cut-and-paste DNA transposon found throughout the tree of life. Buster is a recently recognized family of hAT. However, the evolutionary profile of the Buster family, such as its taxonomic distribution, evolutionary pattern, and activities, remains largely unknown. We conducted a systematic analysis of the evolutionary landscape of the Buster family and found that most Buster transposons are 1.72-4.66 kilobases (kb) in length, encode 500-736-amino acid (aa) transposases and are flanked by short (10-18 bp) terminal inverted repeats (TIRs) and 8 bp target site duplications (TSDs). Buster family is widely distributed in 609 species, involving eight classes of invertebrates and most lineage of vertebrates (including mammals). Horizontal transfer events were detected across multiple phyla and classes of animals, which may have contributed to their wide distribution, and both parasites and invasive species may facilitate HT events of Buster in vertebrates. Our data also suggest that Buster transposons are young, highly active, and appear as intact copies in multiple lineages of animals. High percentages of intact copies (>30%) were identified in some Arthropoda, Actinopterygii, Agnatha, and reptile species, and some of these may be active. These data will help increase understanding of the evolution of the hAT superfamily and its impact on eukaryotic genome evolution.

01 Sep 2017·Journal of Environmental ManagementQ2 · ENVIRONMENTAL SCIENCE & ECOLOGY

Gaseous emissions and modification of slurry composition during storage and after field application: Effect of slurry additives and mechanical separation

Q2 · ENVIRONMENTAL SCIENCE & ECOLOGY

Article

Author: Mendes Ferreira, Luis Miguel ; Santos, Ana Sofia ; Polastre, Adele ; Trindade, Henrique ; Subedi, Raghunath ; Coutinho, João ; Owusu-Twum, Maxwell Yeboah

The aim of the study was to evaluate the impact of slurry treatment by additives (EU200^® (EU200), Bio-buster^® (BB), JASS^® and sulphuric acid (H₂SO₄)) and mechanical separation on the physical-chemical characteristics, gaseous emissions (NH₃, CH₄, CO₂ and N₂O) during anaerobic storage at ∼20 °C (experiment 1) and NH₃ losses after field application (experiment 2). The treatments studied in experiment 1 were: whole slurry (WS), WS+H₂SO₄ to a pH of 6.0, WS+EU200 and WS+BB. Treatments for experiment 2 were: WS, slurry liquid fraction (LF), composted solid fraction (CSF), LFs treated with BB (LFB), JASS^® (LFJ), H₂SO₄ to a pH of 5.5 (LFA) and soil only (control). The results showed an inhibition of the degradation of organic materials (cellulose, hemicellulose, dry matter organic matter and total carbon) in the WS+H₂SO₄ relative to the WS. When compared to the WS, the WS+H₂SO₄ increased electrical conductivity, ammonium (NH₄⁺) and sulphur (S) concentrations whilst reducing slurry pH after storage. The WS+H₂SO₄ reduced NH₃ volatilization by 69% relative to the WS but had no effect on emissions of CH₄, CO₂ and N₂O during storage. Biological additive treatments (WS+EU200 and WS+BB) had no impact on slurry characteristics and gaseous emissions relative to the WS during storage. After field application, the cumulative NH₃ lost in the LF was almost 50% lower than the WS. The losses in the LFA were reduced by 92% relative to the LF. The LFB and LFJ had no impact on NH₃ losses relative to the LF. A significant effect of treatment on NH₄⁺ concentration was found at the top soil layer (0-5 cm) after NH₃ measurements with higher concentrations in the LF treatments relative to the WS. Overall, the use of the above biological additives to decrease pollutant gases and to modify slurry characteristics are questionable. Reducing slurry dry matter through mechanical separation can mitigate NH₃ losses after field application. Slurry acidification can increase the fertilizer value (NH₄⁺ and S) of slurry whilst mitigating the environmental impacts through a decrease in NH₃ losses during storage and after application.

01 Feb 2005·Plant Cell ReportsQ2 · BIOLOGY

Consistent and stable expression of the nptII, uidA and bar genes in transgenic Pinus radiata after Agrobacterium tumefaciens-mediated transformation using nurse cultures

Q2 · BIOLOGY

Article

Author: L. J. Grace ; J. A. Charity ; C. Walter ; L. Holland

An Agrobacterium tumefaciens-mediated transformation protocol has been developed for embryogenic cell cultures of Pinus radiata. Transgenic lines were only produced when embryogenic tissue was placed on nurse tissue during the Agrobacterium co-cultivation and recovery stages of the procedure. Plantlets were regenerated via somatic embryogenesis from ten of the 11 transgenic lines tested and at least 20 of each line were planted in a GMO glasshouse. Expression of the nptII, uidA and bar genes in up to ten plants of each individual transgenic line was evaluated by molecular, biochemical and functional analysis. As expected, expression of the nptII gene varied among the ten lines, while within ten replicates of the same line, nptII expression appeared to be consistent, with the exception of one line, K3. Likewise, the level of GUS activity varied among transgenic lines, but was relatively consistent in plants derived from the same tissue, except for two lines, G4 and G5. Moreover, similar absolute values and pattern of gene expression of uidA was observed in the transgenic plants, for two consecutive years. Plantlets from eight lines survived a spray treatment with the equivalent of 2 kg/ha and 4 kg/ha of the commercial formulation Buster, whereas non-transformed controls died. Southern hybridisation analysis of embryogenic tissue and green needle tissue from putative transgenic lines demonstrated a relatively low number of gene insertions (from one to nine) of both the bar and nptII genes in the nine transgenic lines tested.

News (Medical) associated with SMRX-11

16 Dec 2022

·www.nsmedicaldevices.com

NeuroLogica Installs Next-Generation SmartMSU with OmniTom Elite in the Asia-Pacific Region

NeuroLogica’s SmartMSU with OmniTom Elite, the company’s next-generation mobile stroke unit for imaging on an ambulance, is equipped with a CT scanner to help optimize diagnostic confidence, speed and workflow at the site The OmniTom Elite within the SmartMSU is user-friendly, small in size and delivers high-quality 16-slice CT images including angiography and perfusion head scans. (Credit: Business Wire) NeuroLogica Corp., a subsidiary of Samsung Electronics Co. Ltd., announced the first installation of its SmartMSU with OmniTom Elite – a specialized ambulance that is equipped with a small computed tomography (CT) scanner for head imaging – in the Asia-Pacific region. It was installed in Thailand at the Siriraj Stroke Center, Siriraj Hospital in Bangkok, Thailand under the Mobile Stroke Unit-Stroke One Stop (MSU-SOS) project. Assoc. Prof. Yongchai Nilanont, M.D., Director of Siriraj Stroke Center, Siriraj Hospital states the importance of the Mobile Stroke Unit, MSU-SOS 2023 innovation. “Treatment of cerebrovascular disease is a race against time, as it kills a large number of people worldwide and can cause paralysis in others. The main factor for reducing disability and death is a treatment ‘time standard’ within 270 minutes. If symptoms are reported and diagnosed earlier, the chances of recovery or survival increase. That is why the Mobile Stroke Unit, MSU-SOS 2023, is a powerful tool for medical personnel. The previous MSU has treated 1,070 patients and has saved many lives.” The OmniTom Elite within the SmartMSU boasts an innovative design and features to help emergency medical technicians (EMTs) improve patient care, including: Small Size: Fits in the standard size ambulance and allows for normal workflow for EMTs throughout the vehicle. Safety Mechanisms: Outfitted with a mechanism that secures the device to the vehicle to create additional space around the scanner. It is also equipped with internal radiation shielding to help reduce scatter, providing additional user protection. Improved Workflow: Enables the integration of contrast injectors for optimized workflow when performing CT angiography and CT perfusion, allowing for initiation of scanning and timing of contrast to be performed by the injector. Design Enhancement: Features a redesigned radiolucent interface for the onboard stretcher to allow for minimal movement of the patient when positioning them for head imaging. It is also designed to have low power consumption and is battery-operated to minimize charging. According to the World Stroke Organization, 1 in 4 people will have a stroke in their lifetime. To aid in the early detection of strokes, the mobile stroke unit with diagnostic CT imaging capabilities allows EMTs on board to quickly assess whether a patient is having a stroke caused by a blood clot or hemorrhage. If it’s determined to be caused by a blood clot, the clot-buster tPA (tissue plasminogen activator) can be administered immediately. “The global expansion of the SmartMSU with OmniTom Elite means more healthcare providers will be able to deliver mobile, point-of-care treatment to stroke patients quickly and efficiently,” said Claudia Kleiner, Director of International Sales of NeuroLogica. “We look forward to continuing to expand the community of more than 40 mobile stroke programs worldwide.” Source: Company Press Release

15 Dec 2022

·www.businesswire.com

NeuroLogica Installs Next-Generation SmartMSU™ with OmniTom® Elite in the Asia-Pacific Region

DANVERS, Mass.--( BUSINESS WIRE )--NeuroLogica Corp., a subsidiary of Samsung Electronics Co. Ltd., announced the first installation of its SmartMSU™ with OmniTom ® Elite – a specialized ambulance that is equipped with a small computed tomography (CT) scanner for head imaging – in the Asia-Pacific region. It was installed in Thailand at the Siriraj Stroke Center, Siriraj Hospital in Bangkok, Thailand under the Mobile Stroke Unit-Stroke One Stop (MSU-SOS) project. Assoc. Prof. Yongchai Nilanont, M.D., Director of Siriraj Stroke Center, Siriraj Hospital states the importance of the Mobile Stroke Unit, MSU-SOS 2023 innovation. “Treatment of cerebrovascular disease is a race against time, as it kills a large number of people worldwide and can cause paralysis in others. The main factor for reducing disability and death is a treatment 'time standard' within 270 minutes. If symptoms are reported and diagnosed earlier, the chances of recovery or survival increase. That is why the Mobile Stroke Unit, MSU-SOS 2023, is a powerful tool for medical personnel. The previous MSU has treated 1,070 patients and has saved many lives.” The OmniTom Elite within the SmartMSU boasts an innovative design and features to help emergency medical technicians (EMTs) improve patient care, including: Small Size: Fits in the standard size ambulance and allows for normal workflow for EMTs throughout the vehicle. Safety Mechanisms: Outfitted with a mechanism that secures the device to the vehicle to create additional space around the scanner. It is also equipped with internal radiation shielding to help reduce scatter, providing additional user protection. Improved Workflow: Enables the integration of contrast injectors for optimized workflow when performing CT angiography and CT perfusion, allowing for initiation of scanning and timing of contrast to be performed by the injector. Design Enhancement: Features a redesigned radiolucent interface for the onboard stretcher to allow for minimal movement of the patient when positioning them for head imaging. It is also designed to have low power consumption and is battery-operated to minimize charging. According to the World Stroke Organization, 1 in 4 people will have a stroke in their lifetime. 1 To aid in the early detection of strokes, the mobile stroke unit with diagnostic CT imaging capabilities allows EMTs on board to quickly assess whether a patient is having a stroke caused by a blood clot or hemorrhage. If it’s determined to be caused by a blood clot, the clot-buster tPA (tissue plasminogen activator) can be administered immediately. “The global expansion of the SmartMSU with OmniTom Elite means more healthcare providers will be able to deliver mobile, point-of-care treatment to stroke patients quickly and efficiently,” said Claudia Kleiner, Director of International Sales of NeuroLogica. “We look forward to continuing to expand the community of more than 40 mobile stroke programs worldwide.” To learn more about the SmartMSU with OmniTom Elite, visit here . References: Global Stroke Fact Sheet 2022 (2022). World Stroke Organization: https://www.world-stroke.org/assets/downloads/WSO_Global_Stroke_Fact_Sheet.pdf About NeuroLogica NeuroLogica Corp., the healthcare subsidiary of Samsung Electronics Co., Ltd., develops, manufactures, and markets innovative imaging technologies and is committed to delivering fast, easy and accurate diagnostic solutions to healthcare providers. NeuroLogica is the global corporate headquarters and manufacturer of mobile computed tomography devices. NeuroLogica’s growing portfolio of advanced medical technologies is used worldwide in leading healthcare institutions helping providers enhance patient care, improve patient satisfaction, and increase workflow efficiency. For more information, please visit: www.NeuroLogica.com

Radiation Therapy

100 Deals associated with SMRX-11

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myocardial Infarction	Discovery	-	Institute of Microbial Technology	-
Myocardial Infarction	Discovery	-	Nostrum	-
Thrombosis	Discovery	IN	Nostrum Pharmaceuticals LLC	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

SMRX-11

Overview

Basic Info

Gene Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation